ArticleFrontiers in oncology2026
Inhibition of histone acetyltransferase KAT7 suppresses proliferation and migration of breast cancer cells.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lysine acetyltransferase 7 (KAT7), also known as HBO1 or MYST2, is highly expressed in multiple cancers. This study aims to explore the expression patterns of KAT7 in breast cancer and its impact on phenotypes of breast cancer cells. Methods: The expression of KAT7 and the overall survival of patients were analyzed using the online bioinformatics platform GEPIA2. Immunohistochemistry was applied to detect KAT7 protein expression in breast cancer specimens (94 breast cancer tissues and 12 adjacent normal tissues). KAT7 shRNA plasmids were used to inhibit KAT7 expression in MCF-7 and MDAMB231 cells, and this inhibition was verified by western blot analysis. Cell counting kit-8 (CCK8), colony formation, and transwell migration assays were employed to assess the proliferation and migration of breast cancer cells. Results: KAT7 was highly expressed in breast cancer and correlated with poor patient prognosis. KAT7 expression was significantly higher in breast cancer than in adjacent non-cancerous tissue. 67 of 94 breast cancer samples tested positive for KAT7. KAT7 was significantly negatively correlated with estrogen receptor (ER), progesterone receptor (PR), and Ki67, and was significantly positively correlated with human epidermal growth factor receptor 2 (HER2). KAT7 expression is strongly associated with tumor subtypes. Inhibition of KAT7 significantly suppressed growth, clonogenic formation, and migration in MCF-7 and MDAMB231 cells. Conclusions: Our findings demonstrate that KAT7 was highly expressed in breast cancer, and inhibition of KAT7 suppressed proliferation and migration of breast cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.